Substrates, Inhibitors and Activators of P-glycoprotein: Candidates for Radiolabeling and Imaging Perspectives

Author(s): Nicola A. Colabufo, Francesco Berardi, Maria Grazia Perrone, Elena Capparelli, Mariangela Cantore, Carmela Inglese, Roberto Perrone

Journal Name: Current Topics in Medicinal Chemistry

Volume 10 , Issue 17 , 2010

Become EABM
Become Reviewer
Call for Editor


In recent years, several PET tracers for monitoring the activity and expression of P-gp at the BBB have been tested. P-gp substrates such as [11C]verapamil and [11C]loperamide can be employed to visualize P-gp activity, but they display a moderate baseline uptake in the brain and formation of radiolabeled metabolites which hamper the interpretation of PET data. P-gp inhibitors such as [11C]elacridar, [11C]laniquidar and [11C]tariquidar have been tested to investigate Pgp expression and the results need further investigation. Recently, we developed MC18, MC266 and MC80, that have been characterized as an inhibitor, substrate and inducer of P-gp both by in vitro assays and in the everted gut sac method. These compounds have been radiolabelled with 11C and been evaluated in vivo. In the present review, we compare the outcome of biological in vitro assays and the corresponding in vivo PET data for the P-gp inhibitors [11C]MC18 and [11C]elacridar, the P-gp substrates [11C]MC266 and [11C]verapamil, the P-gp inducer [11C]MC80 and the P-gp modulator cyclosporin A. Since a satisfactory overlap was found comparing in vivo results and the corresponding in vitro findings, the proposed biological in vitro assays could be predictive for the in vivo PET data of novel radiotracers. PET tracers could be employed for various purposes: radiolabeled P-gp inhibitors to monitor decreased expression of P-gp at the BBB in neurodegenerative disorders such as Alzheimers and Parkinsons disease; and radiolabeled P-gp substrates with a high baseline uptake to monitor increased expression of P-gp in epileptic foci.

Keywords: ATPase, PET studies, Caco-2, Rhodamine-123, MCF7/adr cell line, Doxorubicin, Acetoxymethyl ester, Madin-Darby Canine Kidney cells, P-gp expression, [11C]MC80, [11C]MC266, [11C]MC18, Cyclosporin A, Pgp modulators, CYP3A4, P-gp inhibitor, P-gp knock-out mice, Radiometabolites, C]N-desmethyl-loperamide, Radiotracer, P-gp substrates, CYP450, (R)- and (S)-enantiomers, Tariquida, Laniquidar, Elacridar, [99mTc]complexes, [68Ga]complexes, [64Cu]complexes, [11C]loperamide, [11C]verapamil, Multi Drug Resistance (MDR), ATP-Binding Cassette (ABC) transporter family, expression, function, inducer, modulator, substrate, inhibitor, PET, P-glycoprotein

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [1703 - 1714]
Pages: 12
DOI: 10.2174/156802610792928022
Price: $65

Article Metrics

PDF: 17